Ceftolozane
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ceftolozane: From Complicated Urinary Tract Infections to Gonococcal Urethritis
One-Sentence Summary
Ceftolozane is a novel cephalosporin (beta-lactam) antibiotic, clinically used in combination with tazobactam (as Ceftolozane/tazobactam, brand name Zerbaxa) for complicated urinary tract infections and hospital-acquired/ventilator-associated bacterial pneumonia. The TxGNN model predicts it may be effective for Gonococcal Urethritis, with a prediction score of 99.89% — however, 0 clinical trials and 0 publications specifically support this repurposing direction, and mechanistic support is assessed as weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia — based on global drug profile (Zerbaxa); no Singapore registration data available |
| Predicted New Indication | Gonococcal Urethritis |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Ceftolozane is a cephalosporin-class beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) — with particularly enhanced affinity for PBP1b, PBP1c, and PBP3 in Gram-negative bacteria and notable potency against Pseudomonas aeruginosa. In clinical use, it is always combined with the beta-lactamase inhibitor tazobactam to broaden its spectrum against beta-lactamase-producing organisms.
Neisseria gonorrhoeae, the causative agent of gonococcal urethritis, is a Gram-negative diplococcus that is theoretically susceptible to beta-lactam antibiotics — this is the theoretical basis for the TxGNN prediction. The global rise of Ceftriaxone-resistant N. gonorrhoeae (a serious public health concern) has created genuine interest in identifying alternative cephalosporins or beta-lactam combinations, which gives this prediction some contextual relevance as a research question.
However, the mechanistic support for Ceftolozane specifically is assessed as weak. There is minimal published in vitro data characterising Ceftolozane's activity against N. gonorrhoeae, and no PK/PD target-attainment data or clinical evidence for this indication exists. The current standard of care remains Ceftriaxone IM, and Ceftolozane/tazobactam is an IV-only formulation ill-suited for outpatient gonorrhea treatment. This prediction is best interpreted as a speculative signal for drug-resistant gonorrhea research rather than a near-term repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
All Predicted Indications — Overview
The TxGNN model generated 10 candidate indications for Ceftolozane. The mechanistic plausibility varies significantly across predictions:
| Rank | Disease | Score | Evidence Level | Assessment | Rationale Summary |
|---|---|---|---|---|---|
| 1 | Gonococcal Urethritis | 99.89% | L5 | Research Question | Gram-negative coverage theoretically applicable; no clinical data; IV formulation unsuitable for standard outpatient gonorrhea treatment |
| 2 | Ureaplasma Urethritis | 99.89% | L5 | Hold — Mechanism Incompatible | Ureaplasma lacks a peptidoglycan cell wall; beta-lactams are entirely ineffective |
| 3 | Uterine Inflammatory Disease | 99.88% | L5 | Hold | PID requires coverage for Chlamydia (intracellular; beta-lactam-insensitive) and anaerobes; does not match CDC treatment guidelines |
| 4 | Xanthogranulomatous Pyelonephritis | 99.88% | L4 | Research Question | Caused by Gram-negatives (E. coli, Proteus) within Ceftolozane's coverage; 1 indirect review reference; surgery is the primary treatment |
| 5 | Polyclonal Hyperviscosity Syndrome | 99.52% | L5 | Hold — Mechanism Incompatible | B-cell/immunoglobulin disorder; antibiotics have no known effect on immunoglobulin production |
| 6 | Hyperamylasemia | 99.52% | L5 | Hold — Mechanism Incompatible | Biochemical marker of pancreatic/salivary injury, not a bacterial target; no clinical rationale |
| 7 | Urogenital Tuberculosis | 99.50% | L5 | Hold — Mechanism Incompatible | Mycobacterium tuberculosis is intrinsically resistant to cephalosporins due to its unique cell wall lipid layer |
| 8 | Congenital Analbuminemia | 99.44% | L5 | Hold — Mechanism Incompatible | Genetic ALB mutation; antibiotics have no corrective effect on protein synthesis defects |
| 9 | Blood Group Incompatibility | 99.22% | L5 | Hold — Mechanism Incompatible | Red blood cell antigen–antibody reaction; entirely unrelated to antimicrobial mechanism |
| 10 | Premalignant Hematological Disease | 99.11% | L5 | Hold — Mechanism Incompatible | MDS and similar disorders are driven by genomic instability; antibiotics have no therapeutic effect |
Note: 7 of 10 predictions are mechanistically incompatible with Ceftolozane's antibiotic mechanism of action. These high TxGNN scores likely reflect co-morbidity network noise in the knowledge graph rather than true pharmacological signal.
Safety Considerations
Please refer to the package insert for safety information.
(No safety data — including key warnings, contraindications, or drug interactions — was available in this Evidence Pack for Ceftolozane. Package insert retrieval from the global Zerbaxa label is recommended as a priority action.)
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score (99.89%), the evidence level is L5 (model prediction only) with no supporting clinical trials, observational studies, or publications for any of the top-ranked indications. The only biologically plausible candidate (gonococcal urethritis) has weak mechanistic support and faces significant practical barriers (IV-only formulation vs. outpatient disease; no in vitro characterisation against N. gonorrhoeae). The majority of other predictions are mechanistically incompatible and should be deprioritised. Ceftolozane is also not registered in Singapore, and all safety data is currently unavailable.
To proceed with the gonococcal urethritis research question, the following is needed:
- In vitro MIC data: Characterise Ceftolozane's minimum inhibitory concentrations against N. gonorrhoeae, including WHO-designated Ceftriaxone-resistant reference strains
- PK/PD modelling: Determine whether standard Ceftolozane/tazobactam dosing achieves adequate concentrations at the urethral mucosa to eradicate N. gonorrhoeae
- MOA documentation: Retrieve full mechanism of action data from DrugBank API (currently flagged as a data gap)
- Safety data: Download and parse the Zerbaxa international package insert for warnings, contraindications, and drug interactions (currently a blocking data gap)
- Formulation feasibility review: Assess whether an IV antibiotic can be practically positioned for a condition primarily managed in outpatient/STI clinic settings
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.